CureusOct 17, 2026

Starting Glucagon-Like Peptide-1 Therapy and Lifestyle Changes for Severe Obesity in a Patient with Irregular Heartbeats, Joint Pain, and Sleep Apnea

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 18, 2026

Abstract

The patient reduced his body mass index (BMI) from stage 2 to stage 1 obesity over a 12-month period.

Initiation of a GLP-1 receptor agonist and a structured lifestyle modification plan was associated with positive health outcomes.
Blood pressure levels improved and moved into a healthier range.
There were measurable improvements in the patient's lipid profile.
This case highlights the potential benefits of combining pharmacotherapy with behavioral interventions for managing obesity-related health issues.

Simplified

This case report describes a 57-year-old man with morbid obesity, paroxysmal atrial fibrillation, and severe knee osteoarthritis. We discuss the successful optimization of his metabolic and orthopedic risks through the initiation of a glucagon-like peptide-1 (GLP-1) receptor agonist in conjunction with a structured lifestyle modification plan. This case demonstrates the measurable benefit of combining advanced pharmacotherapy with targeted behavioral interventions to manage complex, obesity-related comorbidities. Through the course of a 12-month monitoring period, this patient shifted his body mass index (BMI) from stage 2 to stage 1 obesity, moved his blood pressure to a healthier range, and achieved measurable improvements in his lipid profile.

Full Text

Full text is available at the source.

View Full Text ↗

Starting Glucagon-Like Peptide-1 Therapy and Lifestyle Changes for Severe Obesity in a Patient with Irregular Heartbeats, Joint Pain, and Sleep Apnea

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief